Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | AMEERA-3: SERD for ER+ HER2- breast cancer

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an update on the AMEERA-3 (NCT04059484), ongoing Phase II study of SAR439859, an oral selective estrogen receptor degrader (SERD), versus endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with prior exposure to hormonal therapies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.